Acute Myeloid Leukemia in the Elderly: Results of an Individualized Approach in Two Centres

References

• Harousseau J L. Acute myeloid leukemia in the elderly. Blood Reviews 1998; 12: 145
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Godwin J, McCoiinell T, Slovak M L, Chen I M, Head D R, Appelbaum F R, Willman C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy, A Southwest Oncology Group study. Blood 1997; 89: 3323
   PubMed Web of Science ®Google Scholar
• List A F. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10(Suppl 1)S36
   PubMed Web of Science ®Google Scholar
• Giannoulis N, Ogier C, Hast R, Lindblom B, Sjogren A M, Reizenstein P. Difference between young and old patients in characteristics of leukemic cells: older patients have cells growing excessively in vitro, with low antigenicity despite high HLA-DR antigens. American Journal of Hematology 1984; 16: 113
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda J C, Sierra J, Esteve J, Nomdedeu B, Montserrat E. Treatment of elderly patients with AML: results of an individualized approach. Haematologica 1998; 83: 34
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposed revised criteria for the classification of acute myeloid lcukemia. A report of the French-American-British Cooperative Group. Annals of Internal Medicine 1985; 103: 620
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French- American-British Cooperative Group. Annals of Internal Medicine 1985; 103: 460
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). British Journal of Haematology 1991; 78: 325
   PubMed Web of Science ®Google Scholar
• Swansbury G J, Lawler S D, Alimena G, Arthur Berger D. R, Van den Berghe H, Bloomfield C D, de la Chappelle A, Dewald G, Garson O M, et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genetics Cytogenetics 1994; 73: 1
   PubMed Web of Science ®Google Scholar
• Martinsson P, Nygren P, Fridborg H, Nilsson K, Kristensen J, Larsson R. Cytotoxic activity of cyclosporin A and 13-Keto-Bmt II-[Val 2]- cyclosporin (SDZ PSC 833) on tumour cells from patients with haematological malignancies. European Journal of Clinical Pharmacology 1997; 52: 199
   PubMed Web of Science ®Google Scholar
• Preisler H D. Failure of remission induction in acute myelocytic leukemia. Medical and Pediatric Oncology 1978; 4: 275
   PubMedGoogle Scholar
• Armitage P, Berry D. Statistical methods in medical research.Second edition. Blackwell. 1987
   Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457
   Web of Science ®Google Scholar
• Greenwood M. Reports on public health and medical subjects: The natural duration of cancer. Her Majesty Stationary Office 1926; 33: 1
   Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. British Journal of Cancer 1977; 35: 1
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life tables. Journal of the Royal Statistical Society 1972; 34: 187
   Google Scholar
• Hamblin T. The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome. Leukemia Research 1992; 16: 101
   PubMed Web of Science ®Google Scholar
• Tilly Castaigne H., Bordessoule S. D, Casassus P, Le Prise P Y, Tertian G, Desablens B, Henry-Amar M, Degos L. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology 1990; 8: 272
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell O, Wiernik P, Cooper M R, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison J L, Raich P, Nissen N, Ellison R R, Frelick R, Jams G W, Falkson G, Silver R T, Haurani F, Green M, Henderson E, Leone L, Holland J F. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982; 60: 454
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker A W, Berneman Z N, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hage-Meijer A, Solbu G, Zittoun R. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology 1998; 16: 872
   PubMed Web of Science ®Google Scholar
• Reiffers Huguet J. F, Stoppa A M, Molina L, Marit G, Attal M, Gastaut J A, Michallet M, Lepeu G, Broustet Pris A. J, Maraninchi D, Hollard D, Faberes C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. A prospective randomized trial of idarubicin vs daunorubicin in combination chemo-therapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 1996; 10: 389
   PubMed Web of Science ®Google Scholar
• Rowe J M, Andersen J W, Mazza J J, Bennett J M, Paietta E, Hayes F A, Oette D, Cassileth P A, Stadtmauer E A, Wiernik P H. A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457
   PubMed Web of Science ®Google Scholar
• Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. New England Journal of Medicine 1995; 332: 1678
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P, Lee E J, Moore J O, Powell B L, Schiffer C A. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. New England Journal of Medicine 1995; 332: 1671
   PubMed Web of Science ®Google Scholar
• Witz Sadoun F. A., Perrin M C, Berthou C, Briere J, Cahn J Y, Lioure B, Witz B, Francois S, Desablens B, Pignon B, Le Prise P Y, Audhuy B, Caillot D, Casassus Delain P. M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau J L. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leuceinics Aigues Myeloblastiques (GOELAM). Blnod 1998; 91: 2722
   Google Scholar
• Brito-Babapulle F, Catovsky D, Galton D A. Clinical and laboratory features of de novo acute myeloid leukaemia with tri-lineage myelodysplasia. British Journal of Haematology 1987; 66: 445
   PubMed Web of Science ®Google Scholar
• Goasguen J E, Matsuo T, Cox C, Bennett J M. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Lertkemia 1992; 6: 520
   PubMed Web of Science ®Google Scholar
• Gahn B, Haase D, Unterhalt M, Drescher M, Schoch C, Fonatsch C, Terstappen L W, Hiddemann W, Buchner T, Bennett J M, Wormann B. De novo AML with dysplastic hemat-opoiesis: cytogenetic and prognostic significance. Leukemia 1996; 10: 946
   PubMed Web of Science ®Google Scholar